SEC Filing Analysis: Acrivon Therapeutics, Inc. (ACRV)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Non-discretionary automatic disposition of 294 shares ($585) executed solely to cover mandatory tax withholding on vested RSUs.
• Market Impact: Immaterial; no measurable effect on float, liquidity, or valuation.

Company Information

Field	Value
Company	Acrivon Therapeutics, Inc.
Ticker Symbol	ACRV
CIK	0001781174
Industry	Pharmaceutical Preparations

Insider Information

Field	Value
Name	Mary Miller
CIK	0001841088
Title/Position	Chief Legal Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-10-05
Transaction Code	S (Open market sale)
Security Type	Common Stock
Shares Involved	294
Price Per Share	$1.99
Total Value	$585.06
Shares Owned After	81,715
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$585.06
% of Market Cap ($90M)	0.00065%
Shares Transacted	294
% of Shares Outstanding (42.8M)	0.00069%
Post-Transaction Ownership	81,715 shares (0.19%)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: Across Acrivon's micro-cap valuation of $90 million, a sub-$600 trade has zero financial materiality.
• Ownership Concentration: Mary Miller retains 81,715 shares (0.19% of total shares outstanding), disposing of only 0.36% of her direct equity holding.
• Transaction Significance: The sale is negligible and does not reflect a change in executive sentiment.

Market Impact Analysis

• Stock Impact Prediction: Neutral. The transaction represents standard equity compensation maintenance.
• Expected Volume Impact: Negligible volume impact.
• Sentiment Indicator: Neutral.

Additional Context

• Special Circumstances: The sale was mandated by issuer policy to satisfy tax liability resulting from restricted stock unit vestings, as documented in filing footnotes.